IMMURON LTD-SPON ADR (IMRN)
US45254U1016 - ADR
Immuron Limited to Present at the Emerging Growth Conference
Immuron Limited to Present at the Emerging Growth Conference
MELBOURNE, Australia, May 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated...
Immuron Director Resignation
Immuron Director Resignation
MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated...
Immuron to host Live Virtual Event
Immuron to host Live Virtual Event
MELBOURNE, Australia, April 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated...
Immuron Travelan® sales continued strong growth
Immuron Travelan® sales continued strong growth
Sales Highlights: Global FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcpMar 2024 Quarter AUD$1.3 million up 51%...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out on Thursday to get an idea of the hottest stocks worth watching this morning!
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
Highlights: Immuron proceeding to Phase 3 registration strategy with the FDATravelan® topline clinical trial results demonstrate protective efficacy with...
Immuron Presentation Australian Biologics Festival 2024
Immuron Presentation Australian Biologics Festival 2024
MELBOURNE, Australia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated...
Immuron up 3% on record Travelan sales (NASDAQ:IMRN)
Immuron, an Australian biopharmaceutical company, achieves record sales of Travelan, an immune supplement targeting gastrointestinal bacteria and toxins.
Immuron achieves record Travelan® sales
Immuron achieves record Travelan® sales
Highlights: Travelan® sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 millionAustralian Travelan® YTD Jan 2024 sales $2.1...
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated...
Immuron achieves record half yearly Travelan® sales
Immuron achieves record half yearly Travelan® sales
Highlights: Record half yearly Travelan® sales of $2,334,969Total sales of A$2,355,580 in H1, FY24 $1,771,932 increase on H1, FY23 sales51% higher...
Immuron Clinical Trials Update
Immuron Clinical Trials Update
Highlights: US Naval Medical Research Command (NMRC) campylobacter clinical program completes in-patient phase Manufacture of IMM-529 drug substance to...
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
Highlights: First participants enrolled in the US Naval Medical Research Command Clinical Trial Clinical Study initiated to evaluate the efficacy of a new...
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
MELBOURNE, Australia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated...
Immuron CEO Steven Lydeamore Investor Webinar Presentation
Immuron CEO Steven Lydeamore Investor Webinar Presentation
MELBOURNE, Australia, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated...